LogicBio Therapeutics Inc LOGC:NASDAQ

Last Price$0.37Cboe Real-Time Last Sale as of 9:40AM ET 6/30/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.02(5.15%)
Bid (Size)$0.37 (10)
Ask (Size)$0.39 (100)
Day Low / High$0.37 - 0.40
Volume33.1 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/30/2022

 

LogicBio Therapeutics Inc ( NASDAQ )

Price: $0.37
Change: -0.02 (5.15%)
Volume: 33.1 K
9:40AM ET 6/30/2022
 
 

Protagenic Therapeutics Inc ( NASDAQ )

Price: $0.72
Change: -0.03 (3.63%)
Volume: 726.00
2:09PM ET 6/29/2022
 
 

Neurobo Pharmaceuticals Inc ( NASDAQ )

Price: $0.48
Change: -0.007 (1.41%)
Volume: 3.5 K
3:44PM ET 6/29/2022
 
 

Artelo Biosciences Inc ( NASDAQ )

Price: $0.30
Change: -0.009 (2.83%)
Volume: 7.7 K
10:08AM ET 6/30/2022
 
 

Statera Biopharma Inc ( NASDAQ )

Price: $0.27
Change: -0.0002 (0.07%)
Volume: 208.9 K
10:19AM ET 6/30/2022
 

Read more news Recent News

--Chardan Capital Adjusts LogicBio Therapeutics' Price Target to $4 from $6, Keeps Buy Rating
1:20PM ET 5/17/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q1 Loss $-0.20
8:30AM ET 5/16/2022 MT Newswires

...

-- Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q1 Revenue $2.8M
8:30AM ET 5/16/2022 MT Newswires

...

--William Blair Upgrades LogicBio Therapeutics to Outperform From Market Perform
4:57AM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

LogicBio Therapeutics (LOGC) Investor Presentation - Slideshow
3:04PM ET 5/24/2022 Seeking Alpha

Company Profile

Business DescriptionLogicBio Therapeutics, Inc. engages in the development of genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline include LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA. View company web site for more details
Address65 Hayden Avenue
Lexington, Massachusetts 02421
Phone+1.617.245.0399
Number of Employees23
Recent SEC Filing06/21/20224
President, Chief Executive Officer & DirectorFrédéric Chéreau
VP-Clinical Development OperationsMarie Payton
Chief Financial Officer & TreasurerCecilia Jones
Vice President & Head-Technology DevelopmentMatthias Hebben

Company Highlights

Price Open$0.40
Previous Close$0.39
52 Week Range$0.34 - 5.15
Market Capitalization$12.2 M
Shares Outstanding33.0 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.12
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-468.89%
Return on Equity-104.61%

Analyst Ratings as of 05/06/2022

Buy
3
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset